Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule
默克抗体药物偶联物sac‑TMTmanbetx app苹果 首个三期试验提前告捷

An experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches the patent cliff for its best-selling immunotherapy Keytruda.
默克与manbetx3.0 科伦博泰联合研发的一款实验性抗体药物偶联物首次在一项manbetx app苹果 Ⅲ期临床试验中获得成功，在默克旗下畅销免疫疗法可瑞达即将面临专利悬崖之际，为默克的产品管线带来了一场关键胜利。